English Archives - Page 5 of 10 - Lipum AB (publ) Press Releases

The subscription period in Lipum’s rights issue begins today and the CEO has participated in a company presentation and CEO interview with Erik Penser Bank

Lipum AB (publ) ("Lipum" or the "Company") announces that the subscription period in the Company’s capital raising begins today and runs until July 18, 2023. Lipum wants to inform that Erik Penser Bank has published a company presentation and an interview with the Company's CEO, Einar Pontén. The purpose of the company presentation and interview [...]

2024-03-21T10:14:37+01:00

Lipum publishes an information memorandum in connection with the company’s forthcoming rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS. SEE ALSO THE SECTION "IMPORTANT INFORMATION" [...]

wpadmin2024-03-21T10:14:37+01:00

Lipum AB – Report from the Extraordinary General Meeting

An Extraordinay General Meeting (the ”EGM”) in Lipum AB (publ), corporate identity number 556813-5999 (”Lipum” or the “Company”) today resolved to approve the Board of Directors’ resolution on a rights issue of up to 2,870,334 new shares. On 8 June 2023, the Board of Directors resolved, subject to approval by an EGM, on a rights [...]

2024-03-21T10:14:38+01:00

Lipum has resolved on a rights issue of approximately SEK 26.4 million at a subscription price of SEK 9.20 per share

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS. SEE ALSO THE SECTION "IMPORTANT INFORMATION" [...]

wpadmin2023-06-30T09:20:54+02:00

Lipum AB: BioStock Life Science Spring Summit with Lipum

Do not miss Lipum's presentation at the BioStock Life Science Spring Summit, today May 31 at 10.40. The event starts at 10.00 - see the full programme on BioStock's website (https://www.biostock.se/en/biostock-life-science-summit-may-2023/) or YouTube channel (https://www.youtube.com/channel/UCHXuEgaQtQHZtLCvCJqkT-Q). CEO Einar Ponténwill present Lipum at the BioStock Life Science Spring Summit (https://www.biostock.se/en/biostock-life-science-summit-may-2023/), starting at 10.40. This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

templtokenlogin2024-03-21T10:14:38+01:00

Lipum AB – interim report for the period January-March 2023

Lipum AB (publ) has published the interim report for period January to March for 2023. Below is a summary, a complete report (only in Swedish) is available on the company's website. CEO Einar Pontén comments: “I am excited about our ongoing Phase 1 clinical trial of the drug candidate SOL-116 as everything is going according [...]

2024-03-21T10:14:38+01:00

Lipum AB – Year-end report 2022

Lipum AB (publ) has published the interim and the year-end report for 2022. Below is a summary, a complete report (only in Swedish) is available on the company's website. CEO Einar Pontén comments: “In the fourth quarter, we started a first in man phase 1 clinical trial of our drug candidate SOL-116, achieving the major [...]

2024-03-21T10:14:38+01:00

Lipum’s ongoing clinical phase 1 study proceeds as planned

Lipum AB (publ) announces that the clinical phase 1 study with the drug candidate SOL-116 is proceeding as planned. After a fourth dose escalation, a safety evaluation has now been conducted and as expected, data show that SOL-116 remains safe and well tolerated. The study is therefore continuing as planned with a higher dose level [...]

2024-03-21T10:14:38+01:00

Lipum to participate in following upcoming events

Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming events. BIO-Europe Spring | March 20–22, 2023 | Basel, SwitzerlandLSX World Congress | May 3-4, 2023 | London, UKRedeye Investor Forum | May 11, 2023 | Malmö, SwedenBioStock Life Science Summit Spring | May 30-31, 2023 | DigitalBIO International [...]

2024-03-21T10:14:38+01:00

Lipum AB announces the Nomination Committee for the 2023 Annual General Meeting

Lipum AB (publ) ("Lipum") announces its Nomination Committee for the Annual General Meeting 2023. In accordance with the decision at the Annual General Meeting, the three largest shareholders in terms of voting rights on 1 September 2022 have appointed a Nomination Committee for the Annual General Meeting 2023. The three largest shareholders in terms of [...]

2024-03-21T10:14:38+01:00

Third Party Embeds

Tracking Cookies

Privacy Policy

Contact Information